Draws on international experience across many disciplines offering a practical approach to the topic
Examines the latest advances in surgical and non-surgical management
Discusses molecular studies and translational research and how they have transformed the diagnosis and management of thyroid cancer
Addresses current challenges and areas of controversy such as low risk thyroid cancer and papillary microcarcinoma
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Dr Ujjal Mallick, MBBS MS FRCPE (Hon) FRCP (Hon) FRCR Consultant Clinical Oncologist Formerly Consultant Oncologist and past Chair, Multidisciplinary thyroid cancer team (MDT), Freeman Hospital, Newcastle upon Tyne, UK, a centre of excellence for thyroid cancer. Chief Investigator of the first UK National Thyroid Cancer Trial -Hilo-( NEJM 2012) which helped modify international guidelines and practice and of the on-going second UK trial-IoN. One of the lead authors of the first UK National guideline. The MDT obtained many prestigious national awards including-Best NHS "Hospital Doctor" Oncology Team of the Year" Award 2007, Best Thyroid cancer MDT in NHS Peer Review 2011, first prize in NHS innovations award 2007 and others. He initiated an acclaimed MD clinic involving an expert thyroid cancer patient. Current interests are trials, biomarkers and guideline implementation.
Dr Clive Harmer MB FRCR FRCP. Clinical Oncologist Consultant in Clinical Oncology at St. George's Healthcare NHS Trust and The Royal Marsden NHS Trust (where he was head of the Thyroid unit) until August 2005. Recognized teacher of the University of London and Honorary Senior Lecturer at the Institute of Cancer Research.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur B26ZGREKY4
Quantité disponible : Plus de 20 disponibles
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists. 416 pp. Englisch. N° de réf. du vendeur 9783031386077
Quantité disponible : 2 disponible(s)
Vendeur : moluna, Greven, Allemagne
Etat : New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. N° de réf. du vendeur 2426279545
Quantité disponible : Plus de 20 disponibles
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Practical Management of Thyroid Cancer | A Multidisciplinary Approach | Ujjal K. Mallick (u. a.) | Taschenbuch | xvi | Englisch | 2025 | Springer | EAN 9783031386077 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. N° de réf. du vendeur 133225005
Quantité disponible : 5 disponible(s)
Vendeur : buchversandmimpf2000, Emtmannsberg, BAYE, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - Print on Demand Titel. Neuware -Draws on international experience across many disciplines offering a practical approach to the topicExamines the latest advances in surgical and non-surgical managementDiscusses molecular studies and translational research and how they have transformed the diagnosis and management of thyroid cancerAddresses current challenges and areas of controversy such as low risk thyroid cancer and papillary microcarcinomaSpringer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 416 pp. Englisch. N° de réf. du vendeur 9783031386077
Quantité disponible : 1 disponible(s)
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Taschenbuch. Etat : Neu. Druck auf Anfrage Neuware - Printed after ordering - Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists. N° de réf. du vendeur 9783031386077
Quantité disponible : 1 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. 415. N° de réf. du vendeur 26404348692
Quantité disponible : 4 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. 415. N° de réf. du vendeur 409886923
Quantité disponible : 4 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. 415. N° de réf. du vendeur 18404348702
Quantité disponible : 4 disponible(s)